Close Menu


A*STAR and Tan Tock Seng Hospital developed the test, which is the first diagnostic to be deployed in the country's hospitals since the outbreak began in December.

The company said its Liberty16 device is capable of detecting viral infection quickly, and can be deployed where other PCR instruments are too big to go.

The company will offer a 32-gene polygenic score test to patients in the Osaka, Japan Nakanoshima Clinic, with reporting and patient support help from IxLayer.

The qualitative in vitro nucleic acid amplification assay detects 2019-mCoV using RT-PCR from throat swab and bronchoalveolar lavage fluid samples.

The company said that its 2019-nCoV (SARS-CoV-2) IgG/IgM kits can help labs and hospitals with early diagnosis and elimination of suspicious cases.

A Korean research team is developing a biosensor that boosted sensitivity by using low-cost fabrication to align high-density carbon nanotubes.

As an expert in zoonotic viruses, Poon has published an assay for SARS-CoV-2 as well as a characterization of early infection.

The collaboration will support the development of rapid diagnostics, including point-of-care tests, and therapeutics, according to a statement.

The company is in talks with potential partners in the US and China to validate the assay on clinical samples and deploy it at a large scale.

The urine-based test, which was already available in several markets, does not require any specialized instrumentation and produces results in less than three minutes.